The morning after Li Chuhan's long vigil with the addict Yu Qiang dawned cold and clean, the sky a pale winter blue, the lake a sheet of still silver. Lin Fan woke early, not from the chime of the golden phone but from a dream he couldn't quite remember—something about a hospital corridor that stretched on forever, and a voice calling his name from a room he couldn't reach. He lay in bed for a moment, letting the dream fade, and then he got up and made coffee.
The villa was quiet. Xu Yang had left early for a meeting with a streaming platform that wanted to develop his comedy special—his career was beginning to take off, and Lin Fan felt a quiet pride in his friend's success. The heron stood at its usual spot by the lake, a grey silhouette in the pale light. The koi traced their slow circles. Everything was peaceful, ordinary, unchanged.
At noon, the golden phone chimed with the daily sign-in. Seventy-two million yuan. Lin Fan barely glanced at the screen. He was reviewing personnel files from the pharmaceutical institute, identifying researchers who might be suited for the new antibiotic project. The institute had talented people, but they had been coasting for years on generic drug manufacturing, their skills rusting from disuse. He would need to hire new talent, upgrade the equipment, and create a research culture that rewarded innovation rather than compliance. It was a long-term project, and he was still in the early stages of planning.
Then the golden phone chimed again.
It was not the soft, brief note of the daily sign-in. It was not the crystalline cascade of an occupation card. It was something deeper—a resonant hum that vibrated through the phone and into the bones of his hand, as if the System had been holding its breath for weeks and was finally releasing it. The screen filled with a golden light that was brighter and more intense than anything he had seen before.
*Ding!*
The sound echoed through the kitchen, and then the cards began to appear. Not one card. Not two. A cascade of them, each bearing a fragment of something vast.
`[Beta Protocol: Exceptional Moral Threshold Achieved — Cumulative Assessment.]`
`[Actions assessed during this cycle: Completion of emergency medicine occupation with perfect 5.0 rating, 24 critical interventions, 11 lives saved, establishment of life-debt with high-ranking government official, demonstration of compassionate care principles, restraint in allowing others to lead, ongoing operation of medical debt forgiveness programme, pharmaceutical institute acquisition.]`
`[Cumulative Moral Weighting: Exceptional. This threshold has triggered a landmark Crimson Dividend — the first medical asset of global significance.]`
`[Primary Reward: Full patent rights, molecular specifications, and clinical trial data for "Linfloxacin" — a universal fluoroquinolone-derivative antibiotic effective against all known gram-positive and gram-negative bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and multi-drug-resistant Pseudomonas aeruginosa. The compound is synthetic, scalable, and has demonstrated negligible toxicity in preliminary trials. Estimated development time to market approval: 18-24 months with accelerated regulatory review.]`
`[Secondary Reward: 51% controlling stake in the Shanghai Institute of Pharmaceutical Research — already acquired. This facility will serve as the primary development and manufacturing hub for Linfloxacin.]`
`[Tertiary Reward: Exclusive distribution agreements with three provincial hospital networks in Jiangsu, Zhejiang, and Anhui. These networks will serve as the initial rollout markets for the antibiotic once approved.]`
`[Quaternary Reward: 500 million RMB liquid capital, allocated to the pharmaceutical institute's research budget, specifically earmarked for Linfloxacin's clinical trials and regulatory approval process.]`
`[Note: This distribution represents a significant escalation in the System's asset allocation. Linfloxacin has the potential to save millions of lives worldwide, particularly in regions where antibiotic resistance is a critical public health crisis. The System provides the tools; the host provides the execution.]`
`[Additional Note: With great power comes great responsibility. This phrase is a cliché, but clichés become clichés because they are true. Use this gift wisely.]`
Lin Fan read the cards three times. His coffee grew cold beside him. The heron outside took a single step into the shallows and then stopped, as if it too sensed that something had shifted.
A universal antibiotic. A drug that could kill bacteria that had evolved resistance to every other treatment in the medical arsenal. MRSA, which killed thousands of hospital patients every year. VRE, which plagued intensive care units. Pseudomonas, which infected the lungs of cystic fibrosis patients and the wounds of burn victims. All of them, susceptible to a single compound. The value of such a drug—not just financially, but in human terms—was incalculable.
He thought about the patients he had seen in the emergency room. The homeless man with the infected wound who had nearly lost his arm because the standard antibiotics weren't working. The elderly woman with pneumonia that had resisted three different courses of treatment. The children in the paediatric ward, their immune systems compromised, vulnerable to infections that could sweep through a hospital ward like fire through dry grass. All of them, potentially saveable with a single pill.
He thought about Li Chuhan, who had held a junkie's hand and refused to give up on him. Who had wept over a child she couldn't save. Who had told him, in the quiet of the paediatric ward, that she wasn't sure how much longer she could keep fighting. This drug—this impossible, miraculous drug—could be the thing that reminded her why she had become a doctor in the first place.
He thought about the note from the safe, still on his nightstand, the ink fading from weeks of handling. *May yours be lighter.* The man who had written that note had carried a weight he couldn't bear, and the money had not been enough to save him. But this—this was not just money. This was a weapon against the invisible enemies that killed more people every year than wars and famines and natural disasters combined. This was a way to lighten the weight, not just for one person, but for millions.
He pulled out his regular phone and called the director of the Shanghai Institute of Pharmaceutical Research, a man named Dr. Chen Yong who had been cautiously cooperative since the ownership transfer. "Dr. Chen. I need you to assemble your senior research team. Conference room, two hours. I have something to show you."
"May I ask what this is regarding, Mr. Lin?"
"A new compound. A universal fluoroquinolone derivative. I have the molecular specifications and preliminary trial data. I need a feasibility assessment for clinical trials within the week."
There was a long pause on the other end of the line. "Mr. Lin, with respect—a universal antibiotic is the holy grail of antimicrobial research. Every major pharmaceutical company has been trying to develop one for decades. If you have such a compound, where did it come from?"
"Let's call it an inheritance. I'll explain more when I see you."
He hung up and sat for a moment, staring at the golden phone. The screen was still bright, the cards still visible. He scrolled through the molecular specifications—dense chemical notation that the System had somehow made comprehensible to him, though he had no formal training in organic chemistry. The compound was elegant, almost beautiful in its simplicity. It attacked a protein in the bacterial cell wall that no other antibiotic targeted, a pathway so fundamental that resistance would take decades to evolve, if it ever did. It was, in every sense, a miracle.
But miracles, he was learning, came with burdens. The pharmaceutical industry was not going to welcome a drug that would render most of its existing antibiotic portfolio obsolete. Companies like Pfizer, Merck, and GlaxoSmithKline made billions every year from antibiotics that Linfloxacin would replace overnight. They would fight him—with lawsuits, with regulatory challenges, with lobbying campaigns in every capital where they held influence. The road to market approval would be long and brutal. He would need allies. He would need political cover. He would need the kind of moral authority that came from being undeniably, unassailably on the side of the vulnerable.
And he would need Li Chuhan. Not just as a researcher—she had no background in drug development—but as a moral compass. Someone who would remind him, every day, that the purpose of this drug was not profit but people. Someone who had held dying children in her arms and knew, with absolute clarity, what was at stake.
He picked up his regular phone again and sent her a message: *I have something to show you. It's about the future we talked about. Can you come to the institute tomorrow?*
Her reply came within minutes: *I'll be there.*
He set down the phone and looked out at the lake. The heron was motionless, as always. The koi swam their slow, patient circles. The world was quiet and beautiful and full of problems that a single drug could not solve. But this drug—this impossible, miraculous, terrifying drug—was a start. It was the first stone in an avalanche that would reshape the global pharmaceutical industry, challenge the power of the world's largest corporations, and save millions of lives in the process.
The golden phone chimed softly—a single, quiet note.
`[Remember: The System provides the tools. The host provides the execution. You are not alone in this. But the choices are yours.]`
He put the phone in his pocket and walked out to the car. The Honda's engine hummed to life, and he drove toward the institute, toward the future, toward the long, uncertain road that stretched ahead of him. The weight of what he carried was immense, but it was not unbearable. He had carried other weights before. He was learning to carry them well.